Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture

Summary Brivaracetam (ucb 34714; BRV), a new antiepileptic drug (AED) candidate, is a pyrrolidone derivative displaying a markedly higher affinity than levetiracetam (LEV; Keppra® ) to the synaptic vesicle protein SV2A, shown to be the brain-specific binding site of LEV. The higher affinity for SV2A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Epilepsy research 2010-01, Vol.88 (1), p.46-54
Hauptverfasser:	Zona, Cristina, Pieri, Massimo, Carunchio, Irene, Curcio, Livia, Klitgaard, Henrik, Margineanu, Doru Georg
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticonvulsants - pharmacology Biological and medical sciences Biophysics - methods Brivaracetam (ucb 34714) Cells, Cultured Cerebral Cortex - cytology Dose-Response Relationship, Drug Electric Stimulation - methods Embryo, Mammalian Fast inactivation kinetics Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Ion Channel Gating - drug effects Levetiracetam ( Keppra®) Malformations of the nervous system Medical sciences Membrane Potentials - drug effects Nervous system (semeiology, syndromes) Neurology Neurons - drug effects Patch-Clamp Techniques - methods Pyrrolidinones - pharmacology Rats Sodium Channel Blockers - pharmacology Sodium Channels - physiology Steady-state activation Tetrodotoxin - pharmacology Voltage-activated Na + current
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!